In these three clinical trials, NSCLC patients with strong tumor surface PD-L1 expression (TPS ≧ 50%) who received first-line single ICI therapy (pembrolizumab, atezolizumab, or cemiplimab) had significantly longer survival than control patients receiving conventional chemotherapy [22,28,32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.